Feasibility and acceptability of continuous glucose monitoring in pregnancy for the diagnosis of gestational diabetes: A single-centre prospective mixed methods study

PLoS One. 2023 Sep 27;18(9):e0292094. doi: 10.1371/journal.pone.0292094. eCollection 2023.

Abstract

Background: Undiagnosed diabetes in pregnancy is associated with stillbirth and perinatal complications, but standard testing for gestational diabetes using the oral glucose tolerance test (OGTT) is impractical and exacerbates healthcare inequalities. There is an urgent need to improve the accuracy, acceptability and accessibility of glucose testing in pregnancy. We qualitatively assessed the feasibility and acceptability of two alternative home-based methods of glucose testing in pregnant women, using continuous glucose monitoring (CGM), with or without a home-based OGTT.

Methods: We recruited women with a singleton pregnancy at 28 weeks' gestation with ≥1 risk factor for gestational diabetes attending antenatal glucose testing. A Dexcom G6 CGM device was sited and women were asked to take a 75g OGTT solution (Rapilose) on day 4 after an overnight fast. Qualitative interviews were performed with 20 participants using video conferencing according to a semi-structured interview schedule and thematically analysed using NVIVO software.

Results: 92 women were recruited; 73 also underwent a home OGTT. Women had an average of 6.9 days of glucose monitoring and found the CGM painless, easy to use with few or no adverse events. During the qualitative study, the main themes identified were reassurance and convenience. All women interviewed would recommend CGM and a home OGTT for diagnosis of gestational diabetes.

Conclusions: CGM with or without a home OGTT is feasible and acceptable to pregnant women for diagnosis of gestational diabetes and offered advantages of convenience and reassurance. Further work is needed to clarify diagnostic thresholds for gestational diabetes using CGM metrics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blood Glucose
  • Blood Glucose Self-Monitoring
  • Diabetes, Gestational* / diagnosis
  • Feasibility Studies
  • Female
  • Glucose
  • Humans
  • Pregnancy
  • Prospective Studies

Substances

  • Blood Glucose
  • Glucose

Grants and funding

This study was funded by Diabetes UK through an intermediate clinical fellowship to CLM (17/0005712; ISRCTN number 90795724). CLM is also supported by the EFSD-Novo Nordisk Foundation Future Leader’s Award (NNF19SA058974). Dexcom supplied the CGM systems and some research nurse staff costs to support patient care during the pandemic. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.